DDInter1513 DDInter782
Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Prednisolone {u} (Compound) resembles {v} (Compound) Fluprednidene Acetate
Prednisolone {u} (Compound) resembles {v} (Compound) Hydrocortamate
Prednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Testosterone
Prednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluoxymesterone
Prednisolone {u} (Compound) treats {v} (Disease) chronic obstructive pulmonary disease
Prednisolone {u} (Compound) binds {v} (Gene) NR3C1
Prednisolone {u} (Compound) upregulates {v} (Gene) NFKBIA
Prednisolone {u} (Compound) palliates {v} (Disease) idiopathic pulmonary fibrosis
Prednisolone {u} (Compound) is included by {v} (Pharmacologic Class) Corticosteroid Hormone Receptor Agonists
Prednisolone {u} (Compound) downregulates {v} (Gene) FHL2
Prednisolone (Compound) resembles Fluprednidene Acetate (Compound)
Prednisolone (Compound) resembles Hydrocortamate (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Testosterone
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Fluoxymesterone
Prednisolone (Compound) treats chronic obstructive pulmonary disease (Disease)
Prednisolone (Compound) binds NR3C1 (Gene)
Prednisolone (Compound) upregulates NFKBIA (Gene)
Prednisolone (Compound) palliates idiopathic pulmonary fibrosis (Disease)
Prednisolone (Compound) is included by Corticosteroid Hormone Receptor Agonists (Pharmacologic Class)
Prednisolone (Compound) downregulates FHL2 (Gene)